1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
697439B15263228AB00258AF4003875B4
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-establishing-europe-standards-field-medical-performance-excellence?OpenDocument
18
19OpenDocument
2034.236.191.0
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Establishing EU Standards for Field Medical Performance Excellence

ID: 5800


Features:

10 Info Graphics

31 Data Graphics

610+ Metrics

18 Narratives


Pages/Slides: 47


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Establishing EU Standards for Field Medical Performance Excellence”

STUDY OVERVIEW

The dynamic and rapidly evolving European market is characterized by diverse healthcare systems, regulatory frameworks, and nuanced market dynamics spanning multiple countries. Biopharma manufacturers must implement effective strategies to streamline operations, assess performance efficiently, and understand stakeholder needs to optimize engagement.

Best Practices, LLC undertook this benchmarking research to provide invaluable insights to field medical leaders, empowering them to navigate challenges and capitalize on opportunities within the European market. By delving into key insights and benchmarks, our study offers a roadmap for optimizing field medical operations in Europe. Leveraging a robust dataset, the study further provides segmented insights at the country level, offering valuable benchmarks for the UK, France, Italy, Spain, Germany, and other key EU markets.


KEY TOPICS

  • Effective Field Performance Metrics in Europe
  • Framework for Field Medical Excellence
  • KOL Targeting and Engagement Levels in Europe
  • Average MSL Time Allocation for KOL Interactions and Internal Activities
  • Europe Field Medical Staffing Footprint
  • Key Lessons Learned for Measuring MSL Impact in Europe

KEY METRICS

  • Average total panel size supported by an individual MSL across Europe, including separate figures for the UK, France, Italy, Spain, Germany, and other EU markets
  • Average number of monthly KOL/HCP and F2F meetings in Europe, with specific data for the UK, France, Italy, Spain, Germany, and other EU markets
  • Average time spent in KOL interactions in Europe, along with separate figures for the UK, France, Italy, Spain, Germany, and other EU markets
  • Value assigned to each interaction type on the MSL scorecard across Europe, with individual breakdowns for the UK, France, Italy, Spain, Germany, and other EU markets
  • Optimal and widely utilized field metrics for assessing and showcasing MSL impact across Europe, with details for both the UK, France, Italy, Spain, Germany, and other EU markets
  • Engagement metrics for non-tiered KOLs in Europe, covering both the UK, France, Italy, Spain, Germany, and other EU markets, with separate metrics for each country
  • Average annual field presence of MSLs across Europe, including separate figures for the UK, France, Italy, Spain, Germany, and other EU markets
  • Time spent by MSLs on external, internal, and logistics activities in Europe, with separate breakdowns for the UK, France, Italy, Spain, Germany, and other EU markets
  • Weekly MSL time allocation across activity streams in Europe, with specific data for the UK, France, Italy, Spain, Germany, and other EU markets
  • MSL engagement mix across Europe, including separate breakdowns for the UK, France, Italy, Spain, Germany, and other EU markets
  • Field medical staffing footprint across Europe, with separate figures provided for the UK, France, Italy, Spain, Germany, and other EU markets
  • Span of control: Number of MSLs per MSL manager across Europe, with separate data for the UK, France, Italy, Spain, Germany, and other EU markets

SAMPLE KEY FINDINGS

  • Metrics for Engaging Non-Tiered KOLs in the EU: Throughout EU5, the majority of competitors do not employ specialized metrics to assess non-tiered KOL engagement, with only 9% utilizing such metrics, indicating an area for potential improvement and differentiation.

METHODOLOGY

This study provides benchmarks and insights specific to Europe. The data from this study is drawn from a larger global pool of field leaders, featuring 448 survey responses from 100+ biopharma manufacturers worldwide. The data is meticulously segmented at the region and country level to provide nuanced insights.


Best Practices, LLC also leveraged its propriety Field Medical Excellence database to provide additional benchmarks tailored to align with diverse portfolio considerations.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.